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Background- Colorectal cancer is the third most common cancer in the world. I investigated
the survival rates among colorectal cancer patients diagnosed with hepatic metastasis to see if
any variables are associated colorectal risk and survival.
Methods- Patients were diagnosed from 2000-2019 and collected through MD Anderson’s
database. A descriptive analysis, univariate analysis, Kaplan-Meier with Mantel log-rank test,
Cox proportion hazard regression and a Stratified Cox Model was performed to investigate
death. A competing risk regression was implemented to investigate liver recurrence.
Results- There was a clear difference in the survival outcome between liver surgery patients
and non-liver surgery patients with a 99.1% two-year survival rate for the surgery group and
a 47.1% two-year survival rate for the non-liver surgery group. Though the survival rate is
higher for the 220 liver surgery patients, liver recurrence did occur out of 161 patients and 36
of them has died by end of follow-up. Age of liver diagnosis, extrahepatic metastasis, size
path, synchronous, right colon primary, bilateral metastasis, and the number of liver

metastasis were significantly associated with worse survival. Liver surgery, primary surgery,
and BMI were significantly significant with a greater overall survival in univariate analyses.
The results competing risk regression showed that the log number of liver metastasis (SHR:
1.30, 95% CI: 1.07-1.35) and node positive (SHR: 1.42, 95% CI: 1.08-1.86) were
significantly associated with a poorer result for liver recurrence.
Conclusions- Resection of the liver and primary cancer is an optimal way to treat patient
with colorectal cancer with colorectal cancer with liver metastasis. It is important to note that
even if a patient elects to go through surgery, there is a strong chance that recurrence will
happen. There is also a significant difference in the survival outcome between the patients
who diagnosed with adenocarcinoma of the right colon.
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BACKGROUND
Literature Review
Colorectal cancer is a cancer that starts in the colon or the rectum. The different parts
of the colon include the cecum, ascending, transverse, descending, and the sigmoid colon.
The large intestine is an important organ that of the digestive system. The rectum’s job is to
receive stool from the colon and transport it to the anus. The colon’s job is to absorb water
and salt from the remaining food from the small intestine and passes the remains into the
rectum (American Cancer Society, n.d.). According to the World Cancer Research Fund,
colorectal cancer is the second most common tumor among women and third most common
tumor among men making it the third most common cancer worldwide (2019). In the United
States it is the second leading cause of cancer death in women and the third for men, and it is
estimated that about 1 in 23 women and 1 in 21 men in the United States will be diagnosed
during their lifetime (Jemal et al., 2011). The liver is the most common site for metastasis to
occur from the colorectal cancer (Kow, C. Wei, A., 2019).
Adenocarcinoma
There are different types of cancer in the colon and rectum. The most common type
of cancer is adenocarcinomas, and it makes up about 96% of colorectal cancers (American
Cancer Society). The dataset in this thesis work will only include patients that have been
diagnosed with adenocarcinomas. According to the National Cancer Institute (NIH),
adenocarcinoma is a cancer that starts in the glandular cells that are found in tissue that lines
the internal organs that makes and releases substances in the body.
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Symptoms
There are multiple symptoms that colorectal cancer can cause. Unexplained weight
loss, blood in stool, rectal bleeding, abdomen pain, lump in the abdomen, and changes in
bowel habits are all common symptoms of colorectal cancer (Brazer, 2018). Doctor visit is
recommended if any of these symptoms continue for four weeks or more.
Risk factors
It is still unknown what exactly causes a person to develop colorectal cancer, but
many risk factors are strongly linked to the disease (Cancer Treatment Centers of American,
2020). Older age may increase the risk of colorectal cancer. The majority of the cases are
older than 50, and the rates of colon cancer in people younger than 50 are increasing (Mayo
Clinic, 2019). Around 9 out of 10 people diagnosed with colorectal cancer are aged 50 or
older (Columbia University Herbert Irving Comprehensive Cancer Center, 2019). Inherited
syndromes, gene mutations, are another factor that can increase colon cancer risk and family
history of colon cancer increases your risk. About 5 to 10 percent of people with inherited
gene mutations develop colorectal cancer and four out of ten mutations are in the KRAS gene
(Dinu et al., 2014). Lifestyle is a risk factor as well. Obesity, smoking, diet, Type II diabetes,
lack of physical activity, and high alcohol consumptions are major risk factors (Brazer,
2018). The African American race and Ashkenazi Jews has the greatest risk of colon cancer
than other races do (Columbia University, 2019).
Treatment
Chemotherapy
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Treatment can depend on multiple factors. The most common types of treatment
options include radiation, chemotherapy, and surgery. Systemic chemotherapy drugs are
injected into a vein or by mouth to kill the cancer cells (Kow, C. Wei, A., 2019). This type of
treatment is usually given for cancer that has metastasis. Neoadjuvant therapy is a
chemotherapy treatment given before surgery to help shrink the cancer before surgery and
adjuvant therapy is chemotherapy given after the surgery to help the can cancer from
reoccurring (Columbia University, 2019). The chemotherapy drugs that are commonly used
in in combination to treat: 5-Fluorouracil (5-FU), Capecitabine (Xeloda), Irinotecan,
Oxaliplatin (Columbia University, 2019). These drugs are also used in combination with
VEGF targeted drugs, Bevacizumab (Avastin), and EGFR targeted drugs, Cetuximab
(Erbitux) and panitumumab (Vectibix), to help combat more advanced cancers. The targeted
therapies drugs are given by an infusion and is given one to three weeks at a time depending
on the doctor’s treatment plan (Columbia University. 2019).
Radiation
Radiation is a unique treatment that targets the tumor while reducing the radiation
around the healthy tissues. The treatment can be daily, weekly, every other day, or one single
treatment. The radiation can be given by an external beam radiation, 3D Conformal
radiotherapy, and Intensity modulated radiation therapy (Columbia University. 2019).
Surgery
Colectomy, laparoscopic, and liver resection are all forms of surgery that combat
colon cancer. Colectomy, or colon resection, is the most popular form of surgery when a
person develops colorectal cancer (Columbia University, 2019). It is a procedure were the
3

surgeon removes the part of the colon or rectum that is infected with the cancer and can
remove up to 12 inches of the organ.
A laparoscopic surgery is the standard care for most of the colorectal surgeries. This
is surgery is less invasive and can be conducted with small abdominal incisions (Columbia
University 2019).
Liver resection, or hepatectomy, is a surgery that removes all or a part of your liver.
The liver is divided into two main parts that can be further divided into eight segments. The
liver function is to metabolize drugs and toxins, removes ammonia and bilirubin from the
blood, and synthesis proteins and enzymes (Hyperarts). When surgery of the liver is required,
the most common cancer of the liver that is removed is malignant neoplasms that arise from
the colorectal metastasis (Hyperarts). According to the American Cancer Society, the best
option to cure liver cancer is to perform a hepatectomy. One can live with thirty percent of
liver resected and the liver will grow back to full size over time (Christiano, 2018).
Stages
There are 5 different stages of cancer from stage 0 to stage 4. Stage 0 is the earliest
stage of cancer. This is when the can is still within the inner layer of the colon or rectum.
Stage 1 is where the cancer has grown through the inner layer of the colon or rectum but has
not spread beyond the wall of the organ. Stage 2 is where the cancer has spread through the
wall but has not reach the lymph nodes. Stage 3 is where the cancer has invaded the lymph
nodes but has yet to spread to the other parts of the body. Stage 4 is latest stage of cancer and
it is where the cancer has spread to the other parts of the body (Brazer, 2018).

4

Public Health Significance
Stage IV cancer features a low life expectancy and investigating the significant
impact on public health could help the overall quality of life. According to the American
Cancer Society, the 5-year relative survival rate for patients with stage 4 colon cancer that
has metastasis is 14%. Colorectal cancer is a major public health problem, and anyone could
agree with that.
The cost for one year of treatment for a patient with late stage cancer in the colon are
as high as $310,000 with an annual cost nationwide of $14 billion (Karen, 2015). It is
important to research and implement the most effective treatment to help minimize cost. The
quality of life takes a toll at the population level through the economic burden by the cost of
treatment and the long-term effects of cancer (Cancer Net, 2020).
The American Society of Clinical Oncology (ASCO) provides a resource-stratified
guideline to provide expert suggestion to clinicians for treatment options through different
scenarios. The ASCO strongly suggests that upfront surgery of hepatic metastases and
moderately suggests selective internal radiation therapy with systemic chemotherapy
(Chiorean, et al., 2020). Even though this is the ASCO suggestion, they concluded that there
were some limitations to liver metastases-directed therapies. This is why continuous research
is important to improve the quality of life in cancer patients.
Stage IV colorectal cancer survival rates are low and finding any patterns to increase
the overall quality of life is worth it. With multiple risk factors, treatments, and different
stages of cancer; investigating the treatment outcomes will help determine the best treatment
options to increase the best overall quality of life.
5

Specific Aims
Aim 1. Conduct descriptive analyses and K-sample comparisons to examine the patient
characteristics by subgroups. The subgroups are defined by the primary cancer site, gender
and whether the patient had liver surgery or not.
Aim 2. Conduct univariate analysis and K-sample comparisons to investigate death and liver
recurrence, overall and by whether the patient received liver surgery.
Aim 3. Conduct a semi-parametric multivariable regression model to detect prognostic
factors of liver recurrence and death. A refined Cox model (e.g., stratified proportional
hazards model) will be conducted if the proportional hazards assumption is violated.
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METHODS
Table 1: List of Variables
Variables
Dependent: Surv(time, event)

Description
The dependent variable that will be created
in R that will test a survival object. Time is
for right censor data and event is the status
indicator.
The dependent variable that will be created
to test survival analysis on survival outcome
on the entire data set.
The dependent variable that will be created
to test survival analysis on liver recurrence
for liver resection patients
number of days between liver diagnosis and
the earlier of death and censoring
number of days between liver surgery and
the date of liver recurrence
Patient’s most recent follow-up date
Age of diagnosis of colorectal cancer
Age of diagnosis of liver mets
Male/Female
Mets area outside the colorectal, lymph
nodes, and liver region during the liver
resection.
The date the patient was diagnosis with
colorectal cancer
The date the patient was diagnosis with
liver metastasis.
If the patient had microsatellite instability
If the patient had a KRAS gene Mutation
Weight is collected in grams and height
collected in centimeters to calculate Body
Mass Index
Disease-free interval <6 months from
diagnosis of primary tumor to discovery of
liver metastasis
Patient is alive or not
If the primary tumor is in the colon or
rectum
Specific site of the primary tumor

Dependent: Surv(Futime, Status)

Dependent: Surv(LiverFutime, LiverRecur)

Futime
Liver Futime
Follow up
DxAge
DxAgeLiver
Gender
EhMets

DateDx
DateDxLiver
MSI
KRAS
BMI

Synchronous

Status
Primary
Primary tumor
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Primary Surgery

If the patient had resection on the primary
tumor
If the patient had liver resection
Date of liver surgery
Date of liver recurrence
If the patent had mets in both lobes of the
liver
Size of largest tumor in liver in centimeters
Number of mets in the liver
If the cancer has spread to the lymph nodes
If the patient had hypertension
If the patient had diabetes
If liver recurrence happens after
treatment/surgery

Liver Surgery
Liver surgery date
Date liver Recur
Bilateral
Size path
NoMets
Node Positive
HTN
Diabetes
LiverRecur

Study Subjects
There will be 470 patients from MD Anderson, with 220 that had liver surgery and
250 that did not have liver resection. The data is entered by me, doublechecked by Dr. Chun,
M.D. and is under the oversight of an Institutional Review Board at MD Anderson. The
variables are extracted from MD Anderson’s electronic medical record and stored in Excel
and REDCap. The variables range from basic demographics (sex, date of birth, bmi, and etc.)
to cancer information (number of liver metastasis, size of tumor, location of primary and
metastasis). These data will be de-identified. All patients are diagnosed with a primary
colorectal tumor with metastasis to the liver (stage IV cancer). Eligible patients must have at
least a two-year follow up, unless there is a record that the patient has pass away in that given
time frame.
Data Analysis Plan
The study design of my thesis is to use survival analysis approaches to answer
questions about the dataset. The analysis will be conducted in R version 3.6.0 (R Foundation
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for Statistical Computing, Vienna, Austria). The Type-I error rate will be set at 0.05 for all
planned analyses.
The survival (time to event) outcomes are the time in days since liver metastasis
diagnosis to the time of death. The event indicator will be coded as 1 if the patient died and 0
otherwise. The other outcome is the time in days since liver metastasis diagnosis to liver
recurrence, which is subject to the competing risks censoring by death. We will code the
event indicator as 1 if the patient experience liver recurrence, 2 if the patient dies without
liver recurrence, and 0 if the patient is censored due to other reasons. The death outcome will
be analyzed using classical survival analysis methods in R package survival (Therneau T,
2020), and the recurrence outcome will be analyzed using competing risks methods in R
package cmprsk (Gray, 2020).
Descriptive Analysis
Descriptive analysis will be used first to summarize the data and to find any patterns
in the data. Patient characteristics will be compared across the subgroups, using the
Wilcoxon rank-sum test for continuous variables and the Chi-square test for categorical ones.
Univariate Methods and K-sample Comparisons
Kaplan-Meier curve is an estimate of survival probability at each point in time. This
curve is a purely descriptive method, and it helps to obtain quartiles, medians, and 95%
confidence limits of time to death. It helps to estimate the population survival curve from the
data set and helps compute the fraction surviving at each time. The Kaplan-Meier method
will be used to estimate the survival curve of all the 470 patients with the variable “Status”
equaling 0 as the censored event. For the liver recurrence outcome, I will estimate the
9

cumulative incidence probabilities while treating death as a competing event, using the
cuminc function in R package cmprsk.
Next, we will plot the estimated Kaplan-Meier and cumulative incidence curves by
liver surgery group (Yes/No). The Mantel log-rank test is a comparison of the Kaplan-Meier
curve for more than one group. The log-rank test will be performed to compare the survival
probabilities between patients that had liver resection and those that did not receive surgery.
Similarly, I will apply the Gray’s K-sample test to compare the tumor recurrence outcome
between the two groups.
Multivariable Regression Methods
Cox proportional hazards regression is the model that is more useful than the nonparametric methods that uses multivariate approaches that controls the covariates. This
method is commonly used in medical research for investigating the association between the
survival time of patients and potential risk factors. I will construct a multivariable Cox
proportional hazards model to investigate the association of patient survival time and the
predictors. A full model will be constructed containing all available variables in their optimal
functional form, and an Akaike information criterion (AIC)-based stepwise selection model
will be performed to build model with only the key factors. The liver surgery (Yes/No)
variable will be forced into the model due to its clinical importance. Results will be
summarized by the hazard ratio (HR) and the corresponding 95% confidence intervals.
Next, for the liver recurrence outcome, I will implement competing risks regression
method, using the crr function in R package cmprsk. I will summarize the results in terms of
the HR of the subdistributional hazard and 95% confidence intervals.
10

Model Checking and Refinements
After testing for proportional hazards, I will stratify the model for any variables with
non-proportional hazards. I will verify that all hazards were proportional in the final model.
The final model will be evaluated by several diagnostic methods. A deviance residual plot
could be used to identify outliers in the data and a plot of transformed score residuals could
also be used to check for influential points on the plot.
Human Subjects, Animal Subjects, or Safety Considerations
This thesis project will use de-identified, existing data from the project approved by
the IRBs at Texas MD Anderson Cancer Center and the University of Texas Health Science
Center at Houston. My thesis project has been determined to qualify for exempt status 45
CFR 46.101(b).

RESULTS
Aim 1
Table 2 shows the results for the descriptive analysis between patients that had liver resection
vs. the patients that did not have liver resection. Interesting findings is that the median follow
up time in days is 2228 for the surgical group compared to 685 days for the non-surgical
group. The baseline number of liver metastasis is increased in just the non-surgical group.
The median is 6 liver metastases for the non-surgical group and 2 metastases for the surgical
group. The median for the biggest size path for the non-surgical group was larger at 4.75
centimeters compared to 2 centimeters for the liver surgery groups. These variables could
indicate why a patient was able to receive surgery or not.
11

Table 2: Descriptive Statistics of Liver Surgery Groups
Characteristic

Liver Surgery Group

Non-Surgical Group

Mean

53.2

54.86

Median

54

55

Standard Deviation

11.06

11.7

Min-Max

22-78

26-82

Mean

2260

774.36

Median

2228

685

Standard Deviation

886.25

450.09

Min-Max

763-5142

76-3589

Mean

119.83

485

Median

873.50

329

Standard Deviation

1082.8

436.58

Min-Max

35-4901

56-3589

Mean

29.22

28.17

Median

28.17

27.20

Standard Deviation

6.06

6.12

Age of Liver Diagnosis

Survival Time (Days)

Liver Recurrence Time (Days)

BMI
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Min-Max

18.18-47.97

15.28-55.15

Mean

2.83

5.49

Median

2.00

4.75

Standard Deviation

2.26

3.94

Min-Max

0.3-15.0

0.5-20.30

Mean

3.35

11.36

Median

2

6

Standard Deviation

3.35

12.9

Min-Max

1-21

1-80

Size Path (cm)

Number of Mets

After running the descriptive statistics, I ran Wilcoxon rank-sum test, Pearson
Correlation test, and Chi-square test to see if there are any clear patterns in the dataset. I ran a
Wilcoxon rank-sum test by the liver surgery groups against the continuous variables and I
rejected the null hypothesis against BMI, size path, and the number of metastasis. I also ran
the Wilcoxon rank-sum test by gender and the only variables that were significant was the
age at diagnosis of colorectal cancer and age at diagnosis of liver metastasis. The median age
for women being diagnosis with colorectal cancer is 52 and the median age for men is 55.5.
The rank-sum test was used on the primary site of the cancer (colon/rectum). When running
the analysis, the test was significant with size of the liver metastasis and number of
metastasis.
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The Pearson Correlation test was conducted to correlate the continuous variables in
the dataset. The only two variables that had a significant correlation was size path and
number of metastasis in the liver. It had a p-value of <0.001 and a weak positive correlation
of 0.25.
The Chi-square test was performed to compared categorical variables by subgroup to
see if there is an association between them. After running the test between the liver surgery
groups against gender, KRAS, synchronous, hypertension, diabetes, bilateral metastasis, and
node positive, the only variables that tested significantly at a 0.05 significance level were the
presence of synchronous and bilateral metastasis. There were 260 patients that had bilateral
metastasis only 85 had surgery. The Chi-square test was performed again with the primary
tumor site (right colon, left colon, rectum) and the variables that tested <.05 were gender,
KRAS mutation, and synchronous. It is important to note that 78 out of 234 (33.3%) had a
mutation in the left colon, 53 out of 106 (50%) had a mutation in the Rectum, and 88 out of
130 (66.7%) had a mutation in the right colon.
Aim 2
Aim 2 consists of running a univariate analysis, Kaplan-Meier curves with Mantel Log-Rank
Tests, and Gray’s K-sample test to compare the survival and tumor recurrence outcome.
Table 3 shows the results of the univariate Cox regression analysis for the survival outcome.
Gender, KRAS mutation, Microsatellite instability, hypertension, diabetes, primary tumor
between colon and rectum, and node positive are not associated with mortality at a 0.05
significance level. An older age of liver diagnosis was associated with a 2% increase in
hazard of mortality per year. Liver surgery was associated with an 86% decrease in hazard of
14

mortality compared to patients that did not have any type of liver resection. The presence of
extrahepatic metastasis was associated with an 87% increase in hazard of mortality per year
compared to the absence of extrahepatic metastasis. An increase in BMI was associated with
a 3% decrease in hazard of mortality per year. The increase the largest size of liver metastasis
measured in centimeters was associated with an 11% increase in hazard of mortality per year.
The presence of synchronous was associated with a 74% increase of hazard of mortality
compared to the absence of synchronous. Compared to left colon, primary tumor in the
rectum was not associated with mortality but the presence of a primary tumor in the right
colon was associated with a 37% increase in hazard of mortality relative to left colon (Figure
1). Primary surgery was associated with a 72% decrease in hazard of mortality compared to
patients that did not have colorectal surgery. The presence of bilateral metastasis was
associated with a 67% increase in hazard of mortality compared to the absence of bilateral of
bilateral metastasis. An increase in the number of liver metastasis was associated with a 4%
increase in hazard of mortality.
Table 3: Univariate analysis of each variable.

Dependent: Surv(Futime, Status)

Gender

all

Hazard Ratio (95% CI, p-value)

Female

196 (100.0)

-

Male

274 (100.0)

1.07 (0.87-1.33, p=0.534)

15

Age of Liver Diagnosis

Mean (SD)

54.1 (11.4)

1.02 (1.00-1.02, p=0.003)

Liver Surgery

No

250 (100.0)

-

Yes

220 (100.0)

0.14 (0.11-.18, p<0.001)

No

332 (100.0)

-

Yes

138 (100.0)

1.87 (1.49-2.35, p<0.001)

No

251 (100.0)

-

Yes

219 (100.0)

1.23 (1.00-1.52, p=0.055)

Extrahepatic Mets

KRAS Mutant

BMI

Mean (SD)

28.6 (6.1)

0.97 (0.95-0.99, p=0.002)

Size Path

Mean (SD)

4.3 (3.5)

1.11 (1.08-1.14, p<0.001)

Microsatellite Instability

No

345 (100.0)

-

Yes

46 (100.0)

1.16 (0.82-1.65, p=0.42)

N/A

79

16

Synchronous

Primary

No

79 (100)

Yes

392 (100)

1.74 (1.30-2.33, p<0.001)

352 (100)

-

118 (100)

0.78 (0.61-1.01, p=0.057)

Colon

Rectum

Primary Tumor

Primary Surgery

HTN

Diabetes

Left Colon

234 (100)

Rectum

106 (100)

0.90 (0.68-1.90, p=0.463)

Right Colon

130 (100)

1.37 (1.07-1.76, p=0.012)

No

161 (100)

Yes

309 (100)

No

255 (100)

Yes

215 (100)

No

399 (100)

17

0.28 (0.23-0.36, p<0.001)

0.91 (0.73-1.12, p=0.353)

Yes

Bilateral

71 (100)

1.22 (0.91-1.64, p=0.192)

No

210 (100)

Yes

260 (100)

1.67 (1.34-2.06, p<0.001)

Number of Liver Mets

Mean (SD)

7.6 (10.4)

1.04 (1.03-1.05, p<0.001)

Node Positive

No

113 (100)

Yes

357 (100)

1.20 (0.93-1.53, p=.161)

Figure 1: Kaplan-Meier Curve for the Survival Outcome by Primary Cancer Site
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The second part of Aim 2 was the creation of Kaplan-Meier curves with Mantel Log-Rank
Tests. Figure 1 shows that the primary cancer in the right colon was statistically different
compared the left colon. Figure 2 is the Kaplan-Meier curve of the entire dataset and Figure 3
is Kaplan-Meier curves for the two surgery groups with the Mantel Log-Rank test <.0001
indicating that there is a clear different between the surgical groups. The analysis showed
that 99.1% two-year survival rate (730 days) for the liver surgery group and 47.1% two-year
survival rate for the non-liver surgery group. Figure 4 is the plot of the cumulative incidence
curve. A Kaplan-Meier curve was also conducted between patients who had bilateral
metastasis and those who did not (Figure 5). The Log-Rank test indicates that the two groups
are statistically different. The analysis showed an estimated 64.5% two-year survival rate for
patients that had bilateral metastasis and an estimated 81.4% two-year survival rate for
patients that did not have bilateral metastasis. Extrahepatic metastasis, primary surgery, and
synchronous were also significant when running the Mantel Log-Rank Test (Figure 6,7,8).
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Figure 2: Kaplan-Meier Curve for the Overall Survival

Figure 3: Kaplan-Meier Curve for the Survival Outcome by Liver Surgery Groups
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Figure 4: Cumulative Incidence Curves of Liver Surgery Groups for Death

Figure 5: Kaplan-Meier Curve for the Survival Outcome by Bilateral Metastasis
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Figure 6: Kaplan-Meier Curve for the Survival Outcome by Extrahepatic Metastasis

Figure 7: Kaplan-Meier Curve for the Survival Outcome by Primary Surgery

22

Figure 8: Kaplan-Meier Curve for the Survival Outcome by Synchronous

The third part of Aim 2 was to investigate liver recurrence. Shown in Table 4, we can see
liver recurrence happens often after treatment. A total of 343 of 470 (73%) patients have had
liver recurrence/progression after their treatment, 12% of patients never had recurrence, and
15% of patients died from other cause without having liver recurrence. Running a Gray’s test
for equality of for the competing risk data to investigate liver recurrence, we see that the liver
surgery groups are statistically different for liver recurrence at a p-value of <0.001 and
statistically different for death without liver recurrence at a p-value of <0.001 (Figure 9).
With liver recurrence being coded as 1 and death without liver recurrence being coded as 2,
there was a 73.2% chance that liver recurrence will happen at 1000 days after treatment for
the non-liver surgery group and 51.8% chance that liver recurrence will happen at 1000 days
after treatment for the liver surgery group. There was a 16.2% chance that death without liver
recurrence will happen at 1000 days after treatment for the non-liver surgery group and a
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0.45 percent chance that death without liver recurrence will happen at 1000 days after treat
for the liver surgery group.

Table 4: Liver Recurrence Outcome
Non-Liver Surgery

Liver Surgery Group

Censored

18

39

Liver Recurrence

185

158

Death without Liver Recurrence 47
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Figure 9: Cumulative Incidence Function by Surgery Groups for Liver Recurrence, where 1
Corresponds to Liver Recurrence and 2 Corresponds to Death without Recurrence

Aim 3
The start of Aim 3 is the construction of a multivariable Cox proportional hazard
model to investigate the association of patient survival time and the predictors. An AIC24

based stepwise selection model was performed with the log-transformation for ‘BMI’, ‘Size
Path’, and ‘NoMets’. After building the model, it was found that age of liver diagnosis and
liver surgery predictors had non-proportional hazards. With the ‘DxAgeLiver’ being a
continuous variable, a new variable called ‘age’ was created to categorize age into three
separate groups to help with the stratification. The three age groups where greater than or
equal to 65, in between the ages of 50 and 65, and less than the age of 50 coded as 0, 1, 2,
respectively. The model was stratified on the variable ‘LiverSurgery’ and ‘age’ that resulted
in proportional hazard for the global model. Diagnostic plots showed several outliers with
deviance residuals value just over |2| but none over |3|, and dfbeta plot showed one extreme
outlier on the variable ‘Bilateral’ over |.04| and several extreme outliers on the logtransformation variable ‘BMI’ over |.04|.
It was noted that the presence of bilateral metastasis was associated with a 67% increase in
the hazard of mortality compared to the absence of bilateral metastasis. When included in the
final model, it was no longer statistically significant and when controlling for the other
covariates I proceeded to drop this variable from the final model.
I decided to split the BMI data into ‘Normal’, Under Weight’, ‘Overweight’, ‘Obese’, and
‘Extremely Obese’ (coded 0-4) with the data being compared to normal weight. After
running a univariate analysis, it was concluded that obese and extremely obese patients
where statistically different, but there was a 26% decrease in the hazard for obese patients
and a 50% decrease in hazard for the extremely obese patients (Figure 10). There were 5
underweight, 131 normal weight, 169 overweight, 144 obese, and 21 extremely obese
patients in the dataset. Unexpected weight loss is a symptom of colorectal cancer and it could
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be noted that it could be important to help add weight to a patient before they start their
treatment. According to Jonathan Korcarnik, weight loss was significantly associated with
decreased long-term survivors (Kocarnik et al.). The Center for Disease Control and
Prevention has concluded that 40 percent of cancer diagnosis are associated with being
overweight and obesity (CDC). The dataset includes 334 patients being overweight or higher,
which supports that most of the patients have a larger BMI are diagnosis with cancer. It is
important to note that doctors should help regulated the patient’s weight throughout treatment
and help add weight if the patient is considered underweight. BMI was only collected once
right before treatment. I believe the variable should be dropped from the model and observed
furthermore in future studies by recording if the patient had weight changes throughout
treatment.
Figure 10: Kaplan-Meier Curves for the Survival Outcome by BMI Groups
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It was concluded that bilateral metastasis and BMI had complications and should be excluded
from the final model. After re-running the model with age and liver surgery still stratified,
diagnostic plots (Figure 11, 12) showed several outliers with deviance residuals value over
|2|, and few outliers on the variables extrahepatic metastasis, node positive, and KRAS
mutant over |.02| and one extreme outlier on node positive over |.03| for dfbeta.
Figure 11: Deviance Residuals

Figure 12: DF Beta Residuals

27

A global likelihood ratio test, Wald test, and Score test all returned p-values <0.001,
indicating the significance of the model and that no more covariates need to be removed or
added to the model.
Table 5 details the final model. The variables that were statistically significant
associated with survival time were the log transformation of the number of liver metastasis
and primary surgery of the colorectal cancer. Controlling for the other covariates, I assess the
increase or decrease in hazard for mortality associated with each factor. The hazard was
increase by 23.7% for one log increase in liver metastasis. The hazard will decrease by
36.5% for having primary surgery. The hazard will increase by 54.9% for having the
presence of extrahepatic metastasis before treatment. The hazard will increase by 27.1% for
the presence of having a KRAS mutation and the hazard will increase by 25.3% for the being
node positive. Even though ‘Node Positive’ was not statistically significant, I felt that it was
an important variable to add for the investigations for further studies. The AIC of this model
is 2469.63.
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Table 5: Final Cox PH Model

Dependent: Surv(Futime, Status)

Age of Liver Diagnosis**

Extrahepatic Mets

KRAS Mutation

all

HR (multivariable)

>= 65

96 (100)

-

50-64

213 (100)

-

< 50

161 (100)

-

No

332 (100.0)

-

Yes

138 (100.0) 1.55 (1.22-1.97, p<0.001)

No

Yes

Number of Liver Mets*

Mean (SD)

Node Positive

No

Yes

251 (100.0)

-

219 (100.0) 1.27 (1.02-1.58, p=0.032)

7.6 (10.4) 1.24 (1.10-1.39, p<0.001)

113 (100.0)

-

357 (100.0) 1.25 (0.97-1.62, p=0.083)
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Primary Surgery

Liver Surgery**

No

161 (100.0)

-

Yes

309 (100.0) 0.63 (0.49-0.83, p<0.001)

No

250 (100.0)

-

Yes

220 (100.0)

-

*Log transformation, **Stratified

The last part of Aim 3 was implementing a competing risk regression method. The results are
show in Table 6. With forcing liver surgery and age of liver diagnosis into the model, the
variables of interest that were statistically significant were node positive and the log
transformation of metastasis. With controlling all the other covariates, the presence of node
positive was associated with a 42.1% increase in hazard of liver recurrence and an increase in
the log number of liver metastasis was associated with a 19.8% increase in hazard of liver
recurrence. It is interesting to note, even though was not statistically significant, that the
extrahepatic metastasis is associated with a 19.8% decrease in the hazard of liver recurrence.
This could be due to the fact that it is known that cancer is in other locations of the body and
the current treatment is helping from liver recurrence from happening.
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Table 6: Competing Risk Regression using the Fine and Gray model, where effects are
summarized as the subdistributional hazard ratio (SHR)

Dependent: crr(LiverFutime,
LiverRecure, cbind(x))

Age of Liver Diagnosis

Extrahepatic Mets

KRAS Mutation

all

SHR

>= 65

96 (100)

-

50-65

213 (100)

-

< 50

161 (100)

0.99 (0.85-1.15, p=0.880)

No

332 (100.0)

-

Yes

138 (100.0)

0.78 (0.61-1.01, p=0.063)

No

251 (100.0)

-

Yes

219 (100.0)

1.19 (0.96-1.47, p=0.120)

7.6 (10.4)

1.20 (1.07-1.35, p=0.002)

Number of Liver Mets*

Mean (SD)

Node Positive

No

113 (100.0)

-

Yes

357 (100.0)

1.42 (1.08-1.86, p=.011)
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Primary Surgery

Liver Surgery

No

161 (100.0)

-

Yes

309 (100.0)

1.00 (0.75-1.33, p=0.990)

No

250 (100.0)

-

Yes

220 (100.0)

0.84 (0.62-1.12, p=0.230)

*Log transformation
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FUTURE WORK
To improve the stratified Cox PH model, this study could increase the number of
attributed variables that are significant predictors of survival time. More types of
comorbidities could be added or just having the presence of a condition could be added to the
dataset to help understand the health behaviors associated with colorectal patients. Other
variables to add could be the other types of gene mutations (BRAF, TP53), when and how
many chemo treatments a patient received, family history, race, smoking and alcohol status.
A different direction could focus on BMI more to help understand on whether or not there is
a difference in survival rates between groups. They could focus on whether the patients with
higher BMI is associated with cancer because of their weight and the patients with a lower
BMI is associated with cancer because gene mutations or another cause. It would be
important to track their BMI throughout the treatment process if there is risk when a patient
loses weight during treatment and if it is more common for normal to underweight patients to
lose weight. The other future work could be added more patients to the liver and non-liver
surgery groups, splitting the data between groups, running two separate models, and
observing any clear difference the groups may have.
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APPENDICES
Appendix A:
## Brandon O'Grady - Thesis Project
## 9/4/2020
## Survival Analysis of Colorectal Cancer with Liver Metastasis
########## Libraries ####
library(survival)
library(survminer)
library(tidyverse)
library(dplyr)
library(tidyr)
library(psych)
library(ggplot2)
library(readxl)
library(pastecs)
library(finalfit)
library(cmprsk)
library(kSamples)
########## Load Data Set ####
CRLM <- read_excel("~/Thesis.xlsx")
######### Format Data #####
crlm <- CRLM %>%
mutate(
Gender = factor(Gender, labels = c("Female","Male")),
EhMets = factor(EhMets, labels = c("No Extra Mets", "Extra Mets")),
KRAS = factor(KRAS, labels = c("Non-Kras Mutation", "Kras Mutation")),
Synchronous = factor(Synchronous, labels = c("No", "Yes")),
Primary = factor(Primary, labels = c("Colon", "Rectum")),
PrimarySurgery = factor(PrimarySurgery, labels = c("No", "Yes")),
LiverSurgery = factor(LiverSurgery, labels = c("No Surgery", "Liver Surgery")),
Bilateral = factor(Bilateral, labels = c("No", "Yes")),
NodePositive = factor(NodePositive, labels = c("No", "Yes")),
HTN = factor(HTN, labels = c("Normal", "Hypertension")),
MSI = factor(MSI, labels = c("Microstatellite Stability", "Microstatellite Instability")),
Diabetes = factor(Diabetes, labels = c("No", "Yes")),
PrimaryTumor = factor(PrimaryTumor))
###### Aim 1 #####
##Discriptive Analysis##
#summary of data set#
summary(crlm)
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sd(crlm$DxAgeLiver)
#Descriptive Statistics for whole dataset
stat.desc(crlm)
#Descriptive statistics by Surgical vs. Non-Surgical Groups#
describe.by(crlm,
crlm$LiverSurgery, na.rm = T)
#Descriptive statistics by Gender#
describe.by(crlm,
crlm$Gender, na.rm = T)
#Descriptive Statistics by Primary Tumor
describe.by(crlm,
crlm$PrimaryTumor, na.rm = T)
#Descriptive Statistics by Colon or Rectum
describe.by(crlm,
crlm$Primary, na.rm = T)
### Wilcoxon Rank-Sum test ####
#Liver Surgery vs. Non-Liver Surgery Groups
wilcox.test(BMI ~ LiverSurgery, data = crlm) #Reject the Null
wilcox.test(SizePath ~ LiverSurgery, data = crlm) #Reject the Null
wilcox.test(NoMets ~ LiverSurgery, data = crlm) #Reject the Null
wilcox.test(DxAgeLiver ~ LiverSurgery, data = crlm) #Fail to reject the null
#Gender
wilcox.test(BMI ~ Gender, data = crlm) #Fail to reject the null
wilcox.test(SizePath ~ Gender, data = crlm) #Fail to reject the null
wilcox.test(NoMets ~ Gender, data = crlm) #Fail to reject the null
wilcox.test(DxAgeLiver ~ Gender, data = crlm) #Reject the Null
wilcox.test(DxAge ~ Gender, data = crlm) #Reject the Null
#Rectum or Colon
wilcox.test(BMI ~ Primary, data = crlm) #Fail to reject the null
wilcox.test(SizePath ~ Primary, data = crlm) #Reject the Null
wilcox.test(NoMets ~ Primary, data = crlm) #Reject the Null
wilcox.test(BMI ~ Primary, data = crlm) #Fail to reject the null
### Chi-Square ###
#Liver Surgery vs. Non-Liver Surgery Groups
chisq.test(crlm$Gender, crlm$LiverSurgery) #Fail
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chisq.test(crlm$MSI, crlm$LiverSurgery) #Fail
chisq.test(crlm$KRAS, crlm$LiverSurgery) #Fail
chisq.test(crlm$Synchronous, crlm$LiverSurgery) #Reject the null
chisq.test(crlm$HTN, crlm$LiverSurgery) #Fail
chisq.test(crlm$Diabetes, crlm$LiverSurgery) #Fail
chisq.test(crlm$Bilateral, crlm$LiverSurgery) #Reject the null
chisq.test(crlm$NodePositive, crlm$LiverSurgery) #Fail
table(crlm$LiverSurgery, crlm$Bilateral)
#Gender
chisq.test(crlm$MSI, crlm$Gender) #Fail
chisq.test(crlm$KRAS, crlm$Gender) #Fail
chisq.test(crlm$Synchronous, crlm$Gender) #Fail
chisq.test(crlm$HTN, crlm$Gender) #Reject the null
chisq.test(crlm$Diabetes, crlm$Gender) #Fail
chisq.test(crlm$Bilateral, crlm$Gender) #Fail
chisq.test(crlm$NodePositive, crlm$Gender) #Fail
#Primary Tumor Site
chisq.test(crlm$Gender, crlm$PrimaryTumor) #Reject the null
chisq.test(crlm$MSI, crlm$PrimaryTumor) #Reject the null
chisq.test(crlm$KRAS, crlm$PrimaryTumor) #Reject the null
chisq.test(crlm$Synchronous, crlm$PrimaryTumor) #Reject the null
chisq.test(crlm$HTN, crlm$PrimaryTumor) #Fail
chisq.test(crlm$Diabetes, crlm$PrimaryTumor) #Fail
chisq.test(crlm$Bilateral, crlm$PrimaryTumor) #Fail
chisq.test(crlm$NodePositive, crlm$PrimaryTumor) #Fail
table(crlm$KRAS, crlm$PrimaryTumor)
##### continuous variables ########
cor.test(crlm$DxAgeLiver, crlm$BMI, method="pearson") #not correlated
cor.test(crlm$SizePath, crlm$BMI, method="pearson") #not correlated
cor.test(crlm$SizePath, crlm$NoMets, method="pearson") #correlated at .25
cor.test(crlm$SizePath, crlm$DxAgeLiver, method="pearson") #not correlated
cor.test(crlm$NoMets, crlm$BMI, method="pearson") #not correlated
###########AIM 2##########
###### Univariate Cox-Regression Analysis of Each Variable######
summary(coxph(Surv(Futime, Status) ~ Gender, data = crlm))
summary(coxph(Surv(Futime, Status) ~ DxAgeLiver, data = crlm))
summary(coxph(Surv(Futime, Status) ~ LiverSurgery, data = crlm))
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summary(coxph(Surv(Futime, Status) ~ EhMets, data = crlm))
summary(coxph(Surv(Futime, Status) ~ KRAS, data = crlm))
summary(coxph(Surv(Futime, Status) ~ MSI, data = crlm))
summary(coxph(Surv(Futime, Status) ~ BMI, data = crlm))
summary(coxph(Surv(Futime, Status) ~ Synchronous, data = crlm))
summary(coxph(Surv(Futime, Status) ~ Primary, data = crlm))
summary(coxph(Surv(Futime, Status) ~ PrimaryTumor, data = crlm))
summary(coxph(Surv(Futime, Status) ~ PrimarySurgery, data = crlm))
summary(coxph(Surv(Futime, Status) ~ HTN, data = crlm))
summary(coxph(Surv(Futime, Status) ~ Diabetes, data = crlm))
summary(coxph(Surv(Futime, Status) ~ Bilateral, data = crlm))
summary(coxph(Surv(Futime, Status) ~ SizePath, data = crlm))
summary(coxph(Surv(Futime, Status) ~ NoMets, data = crlm))
summary(coxph(Surv(Futime, Status) ~ NodePositive, data = crlm))
summary(coxph(Surv(Futime, Status) ~ CEA, data = crlm))
### Kaplan-Meier non-parametric analysis
kmsurvival <- survfit(Surv(Futime, Status) ~ 1, data = crlm)
summary(kmsurvival)
ggsurvplot(kmsurvival, data=crlm)
### Kaplan-Meier non-parametric analysis by Liver Surgery group
km_surgery <- survfit(Surv(Futime, Status) ~ LiverSurgery, data = crlm)
summary(km_surgery)
print(km_surgery)
ggsurvplot(km_surgery, data=crlm, pval =T)
#cumulative hazard
ggsurvplot(km_surgery, pval = T, fun = "cumhaz")
#cumulative event by liver surgery group
ggsurvplot(km_surgery, pval = T, conf.int = .95, fun = "event")
### Kaplan-Meier non-parametric analysis by Sex
km_sex <- surv_fit(Surv(Futime, Status) ~ Gender, data = crlm)
summary(km_sex)
ggsurvplot(km_sex, data=crlm, pval = T)
### Kaplan-Meier non-parametric analysis by Rectum and Colon
km_rectum <- surv_fit(Surv(Futime, Status) ~ Primary, data = crlm)
summary(km_rectum)
ggsurvplot(km_rectum, data=crlm, pval = T)
### Kaplan-Meier non-parametric analysis by Site
km_site <- surv_fit(Surv(Futime, Status) ~ PrimaryTumor, data = crlm)
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summary(km_site)
ggsurvplot(km_site, data = crlm, pval = T)
## Kaplan-Meier non-parametric analysis by Bilateral
km_bilateral <- surv_fit(Surv(Futime, Status) ~ Bilateral, data = crlm)
summary(km_bilateral)
ggsurvplot(km_bilateral, data = crlm, pval = T)
print(km_bilateral)
## Kaplan-Meier non-parametric analysis by Synchronous
km_synchronous <- surv_fit(Surv(Futime, Status) ~ Synchronous, data = crlm)
summary(km_synchronous)
ggsurvplot(km_synchronous, data=crlm, pval = T)
## Kaplan-Meier non-parametric analysis by Extrahepatic Mets
km_ehmets <- surv_fit(Surv(Futime, Status) ~ EhMets, data = crlm)
summary(km_ehmets)
ggsurvplot(km_ehmets, data=crlm, pval = T)
## Kaplan-Meier non-parametric analysis by Primary Surgery
km_primarysurgery <- surv_fit(Surv(Futime, Status) ~ PrimarySurgery, data = crlm)
summary(km_primarysurgery)
ggsurvplot(km_primarysurgery, data=crlm, pval = T)
##### Liver recurrence outcome ####
liver_recur <- factor(crlm$LiverRecur, levels = c(0,1,2),
labels = c("Censored", "Liver Recurrence", "Death w/o Liver Recurrence"))
table(liver_recur, crlm$LiverSurgery)
summary(liver_recur)
##Equality of Cumulative Incidence Fuction among Liver Surgery Groups as the grouping
variable
fit <- cuminc(crlm$LiverFutime, crlm$LiverRecur, crlm$LiverSurgery, cencode = 0)
print.cuminc(fit)
plot.cuminc(fit, color = rainbow(4), xlab = "Days")
################ AIM 3 ##############
######## Functional Forms #####
ggcoxfunctional(Surv(Futime, Status)~DxAgeLiver, crlm)
ggcoxfunctional(Surv(Futime, Status)~SizePath, crlm)
ggcoxfunctional(Surv(Futime, Status)~BMI, crlm)
ggcoxfunctional(Surv(Futime, Status)~NoMets, crlm)
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####Normality Check####
##Histograms of Continuous Variables##
#Age of Liver Met Histogram#
ggplot(crlm) +
aes(x = DxAgeLiver) +
geom_histogram()
#BMI Histogram#
ggplot(crlm) +
aes(x = BMI) +
geom_histogram()
#Liver Met Size#
ggplot(crlm.t) +
aes(x = SizePath) +
geom_histogram()
#Number of Liver Mets in Liver#
ggplot(crlm) +
aes(x = NoMets) +
geom_histogram
###Normal Q-Q Plots###
ggqqplot(crlm$DxAgeLiver)
ggqqplot(crlm$BMI)
ggqqplot(crlm$SizePath)
ggqqplot(crlm$NoMets)
###Shapiro-Wilk Test###
shapiro.test(crlm$DxAgeLiver) #can assume normality
shapiro.test(crlm$BMI) #cannot assume normality
shapiro.test(crlm$SizePath) #cannot assume normality
shapiro.test(crlm$NoMets) #cannot assume normality
####Mutate Non-normal variables#####
#log had the best transformations
crlm.t <- crlm %>%
mutate(
age = case_when(
DxAgeLiver >= 65 ~ 0,
DxAgeLiver >= 50 & DxAgeLiver < 65 ~ 1,
DxAgeLiver < 50 ~ 2),
bmi_log = log(BMI),
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size_log = log(SizePath),
size.t = case_when(
size_log >= 1.75 ~ 0,
size_log >= .5 & size_log < 1.75 ~ 1,
size_log < .5 ~ 2),
mets_log = log(NoMets))
crlm.t <- crlm.t %>%
mutate(
size.t = factor(size.t),
age = factor(age))
## Fuctional Form with Transformation
ggcoxfunctional(Surv(Futime, Status)~size_log, crlm.t)
ggcoxfunctional(Surv(Futime, Status)~bmi_log, crlm.t)
ggcoxfunctional(Surv(Futime, Status)~mets_log, crlm.t)

#### Build Model with Improved Functional Forms #####
### Droping MSI due to missing data
cox.mod <- coxph(Surv(Futime,
Status)~age+EhMets+Synchronous+size_log+mets_log+KRAS+
PrimaryTumor+LiverSurgery+HTN+Bilateral+NodePositive+bmi_log+Diabetes+PrimarySu
rgery, data= crlm.t)
summary(cox.mod)
#### AIC-Based Stepwise Model Reduction ####
step.mod <- step(cox.mod, direction = "both") #size_log and size.t were ran and are both
excluded from the model
summary(step.mod)
#### Test Proportional Hazards #####
step.mod %>% cox.zph() %>% ggcoxzph()
cox.zph(step.mod)
#Age of Liver Diagnosis and Liver Surgery will be strata
strat.mod <- coxph(Surv(Futime, Status) ~ strata(LiverSurgery, age) + EhMets + mets_log +
KRAS +
Bilateral + NodePositive + bmi_log + PrimarySurgery, data = crlm.t)
strat.mod
extractAIC(strat.mod)
## Re-check proportional hazards
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strat.mod %>% cox.zph() %>% ggcoxzph() ## All Hazard Proportional, including the global
model
cox.zph(strat.mod)
##### Final model diagnostics ####
## Check dfbeta residuals for model
ggcoxdiagnostics(strat.mod, "dfbeta", title = "DF Beta Residuals")
## Check deviance residuals for model
ggcoxdiagnostics(strat.mod, "deviance", title = "Deviance Residuals")
#Final Report Model
summary(strat.mod)
### oberserving bmi in groups
crlm.t <- crlm.t %>%
mutate(
bmi = factor(bmi, labels = c("Normal", "UnderWeight", "Overweight", "Obese",
"Extremely Obese" )))
summary(coxph(Surv(Futime, Status) ~ bmi, data = crlm.t))
table(crlm.t$bmi)
fisher.test(crlm.t$bmi, crlm.t$LiverSurgery)
km_bmi <- survfit(Surv(Futime, Status) ~ bmi, data = crlm)
summary(km_bmi)
ggsurvplot(km_bmi, data=crlm.t)

####Dropping bmi_log, Bilateral due to complications and significance
#run final model
strat.final <- coxph(Surv(Futime, Status) ~ strata(LiverSurgery, age) + EhMets + KRAS +
mets_log +
NodePositive + PrimarySurgery, data = crlm.t)
strat.final
## Re-check proportional hazards
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strat.final %>% cox.zph() %>% ggcoxzph() ## All Hazard Proportional, including the global
model
cox.zph(strat.final)
##### Final model diagnostics ####
## Check dfbeta residuals for model
ggcoxdiagnostics(strat.final, "dfbeta", title = "DF Beta Residuals")
## Check deviance residuals for model
ggcoxdiagnostics(strat.final, "deviance", title = "Deviance Residuals")
#Final Report Model
summary(strat.final)
extractAIC(strat.final)
### Competing risk regression with the variables of interest###
x <- cbind(crlm.t$age, crlm.t$EhMets, crlm.t$KRAS,
crlm.t$mets_log, crlm.t$NodePositive,
crlm.t$PrimarySurgery, crlm.t$LiverSurgery)
x.cr <- crr(crlm$LiverFutime, crlm$LiverRecur, x)
summary(x.cr)
table(crlm.t$age)
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